Premium
Monitoring the tacrolimus concentration in peripheral blood mononuclear cells of kidney transplant recipients
Author(s) -
Francke Marith I.,
Hesselink Dennis A.,
Li Yi,
Koch Birgit C.P.,
Wit Lucia E.A.,
Schaik Ron H.N.,
Yang Lin,
Baan Carla C.,
Gelder Teun,
Winter Brenda C.M.
Publication year - 2021
Publication title -
british journal of clinical pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.216
H-Index - 146
eISSN - 1365-2125
pISSN - 0306-5251
DOI - 10.1111/bcp.14585
Subject(s) - tacrolimus , medicine , peripheral blood mononuclear cell , nephrotoxicity , whole blood , transplantation , kidney transplantation , immunosuppressive drug , calcineurin , therapeutic drug monitoring , pharmacology , kidney , urology , gastroenterology , immunology , pharmacokinetics , biology , in vitro , biochemistry
Aims Tacrolimus is a critical dose drug and to avoid under‐ and overexposure, therapeutic drug monitoring is standard practice. However, rejection and drug‐related toxicity occur despite whole‐blood tacrolimus pre‐dose concentrations ([Tac] blood ) being on target. Monitoring tacrolimus concentrations at the target site (within peripheral blood mononuclear cells; [Tac] cells ) may better correlate with drug‐efficacy. The aim of this study was to (1) investigate the relationship between [Tac] blood and [Tac] cells , (2) identify factors affecting the tacrolimus distribution in cells and whole‐blood, and (3) study the relationship between [Tac] cells and clinical outcomes after kidney transplantation. Methods A total of 175 renal transplant recipients were prospectively followed. [Tac] blood and [Tac] cells were determined at Months 3, 6 and 12 post‐transplantation. Patients were genotyped for ABCB1 1199G>A and 3435C>T, CYP3A4 15389C>T, and CYP3A5 6986G>A. Data on rejection and tacrolimus‐related nephrotoxicity and post‐transplant diabetes mellitus were collected. Results Correlations between [Tac] blood and [Tac] cells were moderate to poor (Spearman's r = 0.31; r = 0.41; r = 0.61 at Months 3, 6 and 12, respectively). The [Tac] cells /[Tac] blood ratio was stable over time in most patients (median intra‐patient variability 39.0%; range 3.5%–173.2%). Age, albumin and haematocrit correlated with the [Tac] cells /[Tac] blood ratio. CYP3A5 and CYP3A4 genotype combined affected both dose‐corrected [Tac] blood and [Tac] cells . ABCB1 was not significantly related to tacrolimus distribution. Neither [Tac] blood nor [Tac] cells correlated with clinical outcomes. Conclusions The correlation between [Tac] blood and [Tac] cells is poor. Age, albumin and haematocrit correlate with the [Tac] cells /[Tac] blood ratio, whereas genetic variation in ABCB1 , CYP3A4 and CYP3A5 do not. Neither [Tac] blood nor [Tac] cells correlated with clinical outcomes.